Weiss & Lurie, a national class action and shareholder rights law firm with offices in New York City and Los Angeles, is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Anadys Pharmaceuticals, Inc. (NASDAQ: ANDS) arising from its proposed acquisition by Roche Holding for $3.70 per share in cash.

Under the agreement, Roche will commence an all cash tender offer for all outstanding Anadys shares. The tender offer is expected to close within the fourth quarter of 2011, subject to customary conditions, including the tender of a majority of the outstanding Anadys shares.

Weiss & Lurie is investigating whether Anadys’ Board acted in the best interests of its shareholders in approving the transaction. At least one analyst has set a price target of Anadys at $4.00 per share.

If you own Anadys shares and would like more information about your rights as a shareholder or additional information concerning our investigation, please contact Michael A. Rogovin either by email at info@weisslurie.com or by telephone at (888) 593-4771.

Weiss & Lurie has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties. We have recovered over a billion dollars for defrauded institutions and individuals and obtained important corporate governance in these cases. If you have information or would like legal advice concerning possible corporate wrongdoing (including insider trading, waste of corporate assets, accounting fraud, or issuing materially misleading information), consumer fraud (including false advertising, defective products, or other deceptive business practices), or anti-trust violations, please email us at info@weisslurie.com or fill out the form on our website, http://www.weisslurie.com/contact/report_fraud/. Attorney Advertising. Past results do not guarantee a similar outcome.

Copyright Business Wire 2010

If you liked this article you might like

7 Stocks Hitting New 52-Week Highs

7 Stocks Hitting New 52-Week Highs

Roche's All-Oral Hep C Therapy Could Be First, Not Best, to Reach Market

Roche's All-Oral Hep C Therapy Could Be First, Not Best, to Reach Market

Roche-Anadys Hookup Could Spark More Hep C Acquisitions

Roche-Anadys Hookup Could Spark More Hep C Acquisitions

Anadys To Be Bought by Roche for $230M

Anadys To Be Bought by Roche for $230M

Hep C Drug Updates: Vertex and Anadys

Hep C Drug Updates: Vertex and Anadys